Patient characteristics (N = 110)
| Characteristic . | No. . | Median (range) . |
|---|---|---|
| Sex | ||
| Male | 68 | |
| Female | 42 | |
| Age, y | 12 (2-61) | |
| 2-14 | 71 | |
| 15-61 | 39 | |
| Pretreatment disease burden | ||
| Percent blasts in BM by morphology | 8.75 (0-96) | |
| <5 | 42 | |
| 5 to ≤20 | 14 | |
| >20 | 44 | |
| With EMD | 23 | |
| CNS leukemia | 17 | |
| CNS-2 | 5 | |
| CNS-3 | 4 | |
| Testicular leukemia | 4 | |
| Diffused EMD | 3 | |
| Single-site EMD | 2 | |
| Complex cytogenetic | 53 | |
| With fusion gene | ||
| BCR-ABL | 14 | |
| TEL-AML1 | 8 | |
| E2A-PBX1 | 6 | |
| E2A-HLF | 3 | |
| With gene mutation | ||
| IKZF1 | 10 | |
| TP53 | 12 | |
| Other | 39 | |
| Disease status | ||
| Refractory (median of 3 cycles of chemotherapy) | 14 | |
| Relapsed (median of 10 cycles of chemotherapy) | 96 | |
| Transplant status | ||
| Posttransplant relapse | 16 | |
| No previous transplant | 94 |
| Characteristic . | No. . | Median (range) . |
|---|---|---|
| Sex | ||
| Male | 68 | |
| Female | 42 | |
| Age, y | 12 (2-61) | |
| 2-14 | 71 | |
| 15-61 | 39 | |
| Pretreatment disease burden | ||
| Percent blasts in BM by morphology | 8.75 (0-96) | |
| <5 | 42 | |
| 5 to ≤20 | 14 | |
| >20 | 44 | |
| With EMD | 23 | |
| CNS leukemia | 17 | |
| CNS-2 | 5 | |
| CNS-3 | 4 | |
| Testicular leukemia | 4 | |
| Diffused EMD | 3 | |
| Single-site EMD | 2 | |
| Complex cytogenetic | 53 | |
| With fusion gene | ||
| BCR-ABL | 14 | |
| TEL-AML1 | 8 | |
| E2A-PBX1 | 6 | |
| E2A-HLF | 3 | |
| With gene mutation | ||
| IKZF1 | 10 | |
| TP53 | 12 | |
| Other | 39 | |
| Disease status | ||
| Refractory (median of 3 cycles of chemotherapy) | 14 | |
| Relapsed (median of 10 cycles of chemotherapy) | 96 | |
| Transplant status | ||
| Posttransplant relapse | 16 | |
| No previous transplant | 94 |